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The presence and potential adverse effects of
pharmaceuticals in the aquatic environment
have begun to receive increasing attention in
the popular and scientiﬁc press in recent years.
This increase is largely a result of a number of
scientific papers published in the 1990s that
reported trace levels of pharmaceuticals
detected in environmental samples, including
sewage effluent, surface water, groundwater,
and even drinking water, mainly in European
countries (Buser etal. 1998; Daughton and
Ternes 1999; Halling-Sorensen etal. 1998;
Heberer 2002; Jones etal. 2001; Kolpin etal.
2002; Ternes 1998; Ternes etal. 1999). The
existence of pharmaceuticals in the U.K.
aquatic environment has been established, but
the extent of their distribution and the possible
ecotoxicologic consequences associated with
their presence are less clear. Pharmaceuticals
are produced and used in very large volumes,
and their use and diversity are increasing every
year. Estimates based on the number of pre-
scriptions issued suggest that around 100 tons
of drugs were prescribed in Germany in 1995
(Ternes 1998). In the United Kingdom in
2000, use exceeded 10 tons/year for each of
the top 25 compounds, and the amount of the
top three compounds prescribed [aceta-
minophen (paracetamol), metformin hydro-
chloride, and ibuprofen] was > 100 tons/year
each (Jones etal. 2002). Recent research has
shown that these compounds could have a
negative effect on the aquatic environment
(Jones etal. 2003). Observed environmental
effects are limited mainly to the feminizing
activity of endocrine-disrupting compounds
such as the synthetic hormone 17α-ethinyl
estradiol on fish near wastewater treatment
works (WWTW) outfalls (Jobling etal. 1998;
Länge etal. 2001; Routledge etal. 1998).
Other concerns include the development of
antibacterial resistance either in or near
WWTWs (Schwartz etal. 2002) or in the
environment as a consequence of veterinary
drug use (Petersen etal. 2002). Detection of
these negative effects in the environment is dif-
ﬁcult; although in vivo and in vitro laboratory
tests generally show that the toxic effects of
these compounds are not seen at the low levels
currently detected in the environment, the
possibility of variations in sensitivity, chronic
exposure, and mixture effects such as concen-
tration addition and synergism (Altenburger
etal. 2004; Cleuvers 2004; Richards etal.
2004) mean that other negative effects cannot
be ruled out. As a result, risk assessment
guidance has been developed to predict the
environmental impact caused by new pharma-
ceuticals [Bound and Voulvoulis 2004;
European Agency for the Evaluation of
Medicinal Products (EMEA) 2005; U.S. Food
and Drug Administration (FDA) 1998].
There are two main routes for pharmaceu-
ticals to enter the environment. The ﬁrst is via
the effluent from WWTWs after excretion
from the body (Figure 1). After administration,
a significant proportion of a pharmaceutical
may pass through the body unmetabolized.
The degree to which a compound is changed
in the body depends on its structure and
mechanism of action. The β-blocker nadolol
may pass through the human body completely
unmodiﬁed (RxList 2005a). In contrast, only
3% of the parent form of the antiepileptic
carbamazepine is excreted unchanged in the
urine (RxList 2005b); the rest may be conju-
gated or hydroxylated and also released in the
feces. Release via this pathway is governed by
the pharmacology of the drug and the effi-
ciency of the WWTW. Excretion rates of
many pharmaceuticals, such as those shown in
Table 1, can be found in both medical
(Martindale 1993) and environmental litera-
ture (Calamari etal. 2003; Jjemba, in press).
The exact rates also depend on the dosage and
the physiology of the individual.
Data on WWTW removal efﬁciencies are
sparse and are largely dependent on the facili-
ties at individual WWTWs and on variables
such as local rainfall and temperature
(Table 2). For example, only 9% of diclofenac
was found to be removed by biologic filtra-
tion, whereas 75% was removed by activated
sludge treatment (Stumpf etal. 1999). Because
these data are required by the draft European
Union guidelines on risk assessment (EMEA
2005), there will presumably be an increase in
research in this area.
The second route by which pharmaceuti-
cals can enter the environment is by the dis-
posal of out-of-date or unwanted medicines,
which may occur via the sink/toilet or in
household waste that is then taken to landﬁll
sites (Figure 1). Entry into the environment by
this route is dependent on the habits of the
patient and the efﬁciency of prescription prac-
tices leading to fewer unﬁnished prescriptions.
Discarded pharmaceuticals are deﬁned in the
United Kingdom by the Controlled Waste
Regulations 1992 [Her Majesty’s Stationery
Ofﬁce (HMSO) 1992] as clinical waste and as
such are controlled by the Special Waste
Regulations 1996 (HMSO 1996). According
to this legislation, such waste may be disposed
of in landfill sites designed to accommodate
hazardous waste, or it may be incinerated.
However, once dispensed to or purchased by
a member of the public, any unwanted phar-
maceutical products are classified as house-
hold waste, and their disposal is not subject to
any controls. Manufacturer packaging usually
recommends disposal by returning to the
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Pharmaceuticals are produced and used in increasingly large volumes every year. With this growth
comes concern about the fate and effects of these compounds in the environment. The discovery
of pharmaceuticals in the aquatic environment has stimulated research in the last decade. A wide
range of pharmaceuticals has been found in fresh and marine waters, and it has recently been
shown that even in small quantities, some of these compounds have the potential to cause harm to
aquatic life. The primary pathway into the environment is the use and disposal of medicines;
although much of the research in the area currently focuses on the removal of pharmaceuticals
during sewage treatment processes, disposal via household waste might be a signiﬁcant pathway
requiring further research. To investigate the household disposal of unused and expired pharma-
ceuticals as a source of pharmaceutical compounds in the environment, we carried out a survey
and interviewed members of 400 households, predominantly from southeastern England. We used
the information on when and how they disposed of unﬁnished pharmaceuticals to construct a con-
ceptual model to assess the pathways of human pharmaceuticals into the environment. The model
demonstrated that disposal of unused pharmaceuticals, either by household waste or via the sink
or toilet, may be a prominent route that requires greater attention. Key words: drugs, prescrip-
tions, risk assessment, survey, wastewater treatment. Environ Health Perspect 113:1705–1711
(2005). doi:10.1289/ehp.8315 available via http://dx.doi.org/ [Online 9 August 2005]pharmacist; however, disposal via the sink/toilet
or in normal household waste is common.
Pharmaceuticals in landﬁll sites are subject to
biologic degradation processes, but some may
persist and even leach into surrounding
groundwater and rivers (Ahel etal. 1998; Holm
etal. 1995; Schwarzbauer etal. 2002).
An investigation into the disposal habits of
the American public found that only 1.4% of
the people they surveyed returned unused
medication to the pharmacy, whereas 54%
threw them away and 35.4% disposed of them
in the sink/toilet (Kuspis and Krenzelok 1996).
These methods of disposal result from U.S.
Drug Enforcement Administration regulations
that strictly control the transfer of drugs and
controlled substances. It is possible for some
institutions to return unwanted drugs via orga-
nizations afﬁliated with the Returns Industry
Association, a group of licensed “reverse dis-
tributors” that offer a return and disposal ser-
vice (Daughton 2003b). Although regulations
vary among U.S. states, most pharmacies can-
not accept returns from patients. Measures to
allow the return of unused medication from
long-term care facilities have been passed or are
being considered in some states. Developments
in legislation are listed on the National
Conference of State Legislatures website
(NCSL 2005). Some states will also allow the
redistribution of drugs within their expiration
date, although they do not permit the return of
drugs by private individuals. This service is
therefore limited largely to medicines that
never leave pharmacies and care facilities. 
A source of concern is that, at the pharma-
cies questioned, 68% of unreturnable medi-
cines were disposed of in nonhazardous waste
or via the drain. Traditionally, disposal advice
to consumers has been limited to flushing
down the toilet or, in some cases, burning or
grinding and discarding in household waste
(Pray and Pray 2004), but emerging environ-
mental concerns mean that this is sometimes
modiﬁed (Daughton 2003b). People are ﬁrst
advised to check whether local pharmacies or
doctors are able to receive returns or whether
hazardous waste facilities exist in the area. As a
last resort, disposal in household waste is
deemed to be less harmful than disposal via
the sewage system (Boehringer 2004). A study
by Braybrook etal. (1999), designed to exam-
ine ways to streamline the prescription process
in order to reduce costs, looked at some of the
reasons people gave for returning unused
pharmaceuticals to the pharmacy. The most
common reason was a change of medication.
Most items (80%) were returned within a year
of their prescription date, but some people
returned the medicines only after the infre-
quent removal of unwanted items that have
built up over time, with some products being
returned 13 years after they were dispensed.
The aim of the present study was to iden-
tify and assess the signiﬁcance of the different
pathways of pharmaceuticals from the house-
hold to the environment. Knowledge of the
motivation behind different disposal methods
is useful in the management of the release of
pharmaceuticals in the environment and in the
assessment of the associated risk. This project
aimed to demonstrate the possible importance
of household disposal of unused medicines as a
pathway into the aquatic environment.
Materials and Methods
Pharmaceuticals are a large and varied class of
compounds with diverse properties and appli-
cations. To facilitate their study, they are often
grouped by their therapeutic action. We tar-
geted eight therapeutic groups in this study.
We used various criteria, including volume of
prescription, toxicity, and evidence of presence
in the environment, in the selection process.
Table 3 presents a summary of the factors that
cause concern (risk indicators), with examples
of pharmaceuticals within the groups.
A survey was devised to investigate disposal
patterns of the eight selected groups of phar-
maceuticals. This survey was part of a study
into the disposal of household hazardous waste
supported by the Environment Agency of
England and Wales (Slack etal. 2005b).
Respondents were asked whether they ever had
any of the types of medicines and when and
how they disposed of them. Information about
the age, sex, education, profession, and postal
code of the respondent in order to assess socio-
economic status was collected. Respondents
gave their written informed consent to this
information being used anonymously in our
study. Only closed-ended questions were used,
with the questioner specifying possible
answers. These questions have the advantages
of being quick to administer, easy to answer,
and easier to analyze and interpret than are
open-ended questions (Petersen 2000). Where
list questions were employed, no limit was
placed on the number of answers that could be
given, so that respondents were not required to
choose a single answer when it did not wholly
represent their attitude or behavior.
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Table 1. Urinary excretion rates of unchanged active ingredient for selected pharmaceuticals.
Therapeutic Parent compound 
Drug class excreted (%) Reference
Ibuprofen Painkiller 10 Dollery 1991
Paracetamol Painkiller 4 Huschek et al. 2004
Amoxycillin Antibacterial 60 Martindale 1993
Erythromycin Antibacterial 25 Huschek et al. 2004
Sulfamethoxazole  Antibacterial 15 Hirsch et al. 1999
Atenolol β-Blocker 90 Dollery 1991
Metoprolol β-Blocker 10 Huschek et al. 2004
Carbamazepine Antiepileptic 3 Huschek et al. 2004
Felbamate Antiepileptic 40–50 RxList 2005c
Cetirizine Antihistamine 50 RxList 2005d
Bezaﬁbrate Lipid regulator 50 Ternes 1998
Domestic
household
Disposal Usage
Body
Toilet Sink/toilet Pharmacy Household waste
WWTW Landfill
Leaching to groundwater
Surface water
Biosolids
spread on land
Treated leachate
discharged to river
Chemical and
biologic
degradation plus
leachate treatment
Metabolism
(e.g., conjugation
and
hydroxylation)
Biologic and
chemical
degradation,
removed as
sludge
Figure 1. Pathways of drug fate from domestic households to the environment.Using Equation 1 and the method of
McCall (1982), we calculated that the num-
ber of respondents required to obtain a repre-
sentative sample, n, was 384. We divided the
total population into four groups: those who
lived in population centers of ≥ 250,000
(cities), 249,999–50,000 (very large towns),
49,999–10,000 (mid-sized towns), and < 9,999
(small towns/villages). The numbers of people
estimated to live in each type of area were
extrapolated down and applied to the sample
size in order to achieve a representative spread:
n = π (1 – π) z2/e2, [1]
where n is the estimated sample size required
for desired precision and conﬁdence, 384; π is
the preliminary estimate of proportion
opposed to this initiative within the popula-
tion, 0.5; z is the two-tailed value of the stan-
dardized normal deviation associated with the
desired level of confidence; and e is the
desired precision, half the maximum accept-
able conﬁdence interval, here 0.05.
We used a model based on the flow dia-
gram in Figure 1 to quantify the amount of
pharmaceuticals that reach the environment by
the various pathways shown. The division
between the use and disposal of drugs is based
on responses from subjects who said they ﬁn-
ished the prescription and therefore had noth-
ing to dispose of and those who said they
disposed of drugs at another time (e.g., when
the drug expired). Because it was difficult to
collect information on the proportion of these
medicines that were used before disposal, a
number of assumptions had to be made. The
main assumption was that subjects who said
that they had some medicine to dispose of ﬁrst
consumed 50% of the prescription, disposing
of the remaining 50%. We also assumed that
all prescriptions of each individual drug con-
tained the same quantity and strength of drugs.
These assumptions limit the accuracy of the
present model. The most reliable way to estab-
lish the proportion of prescriptions that remain
unﬁnished and the method of disposal chosen
would be to collect unwanted medicines
directly from households. 
As with any survey, the quality of the
results depends on on the truthfulness of the
responses. Forgetfulness and embarrassment
about socially stigmatized medication, for
example, may lead to misreporting and incor-
rect estimates. People may feel pressured to
give the answers that they think are the
“right” ones, those that are more socially
acceptable, or those that they believe the
questioner wants to hear. This was minimized
by the passive questioning style, with as little
prompting as possible. In a review of the
accuracy of patient self-reporting, Evans
and Crawford (1999) found mixed results:
patient recall, as one might expect, was more
reliable over short time periods and less so in
elderly patients. 
We did not request specific data about
types and amounts of medication, so the
reported data should be less affected by these
problems. If such information was required, a
patient diary for recording all incidences of
medication would be the most effective way
of obtaining it. The answers relating to
behavior are less dependent on recall and
more dependent on opinion and personal
preference. However, a patient diary would
Pathways for drugs into the aquatic environment
Environmental Health Perspectives • VOLUME 113 | NUMBER 12 | December 2005 1707
Table 2. Removal of selected pharmaceuticals in WWTWs.
Drug Percent WWTW removal Treatment process Reference
Bezaﬁbrate 99.5 Activated sludge Kreuzinger et al. 2004
83 Activated sludge Ternes 1998
50 Activated sludge Stumpf et al. 1999
27 Biologic ﬁlter Stumpf et al. 1999
Carbamazepine 10 Activated sludge Kreuzinger et al. 2004
7 Activated sludge Ternes 1998
Diclofenac 75 Activated sludge Stumpf et al. 1999
69 Activated sludge Ternes 1998
9 Biologic ﬁlter Stumpf et al. 1999
0 Average of 7 WWTWs Lee et al. 2003
17α-Ethinyl estradiol 78 Activated sludge Ternes et al. 1999
64 Biologic ﬁlter Ternes et al. 1999
Gemﬁbrozil 69 Activated sludge Ternes 1998
46 Activated sludge Stumpf et al. 1999
16 Biologic ﬁlter Stumpf et al. 1999
5 Average of 7 WWTWs Lee et al. 2003
Ibuprofen 99 Activated sludge Kreuzinger et al. 2004
90 Activated sludge Ternes 1998
87 Average of 7 WWTWs Lee et al. 2003
80–100 Activated sludge Kanda et al. 2003
75 Activated sludge Stumpf et al. 1999
60–70 Activated sludge Carballa et al. 2004
65 Biologic ﬁlter Rodriguez et al. 2003
22 Biologic ﬁlter Stumpf et al. 1999
14–44 Biologic ﬁlter Kanda et al. 2003
Indomethacin 40 Average of 7 WWTWs Lee et al. 2003
Ketoprofen 69 Activated sludge Stumpf et al. 1999
48 Biologic ﬁlter Stumpf et al. 1999
18 Average of 7 WWTWs Lee et al. 2003
Metoprolol 83 Activated sludge Ternes 1998
Naproxen 78 Activated sludge Stumpf et al. 1999
70 Average of 7 WWTWs Lee et al. 2003
66 Activated sludge Ternes 1998
40–55 Activated sludge Carballa et al. 2004
45 Biologic ﬁlter Rodriguez et al. 2003
15 Biologic ﬁlter Stumpf et al. 1999
Propranolol 96 Activated sludge Ternes 1998
Sulfamethoxazole 67 Activated sludge Carballa et al. 2004
Table 3. Selected pharmaceutical groups and their environmental risk indicators.
Drug Examples Risk indicator References
Painkillers NSAIDS (e.g., ibuprofen), Very high prescription and  Buser et al. 1999
other analgesics (e.g., OTC volumes; detected 
acetaminophen) in the environment
Antibiotics Penicillins, High volumes; detected Berger et al. 1986
sulfamethoxazole in the environment; Hirsch et al. 1999
concerns over toxicity Leff et al. 1993
and antibacterial resistance Wollenberger et al. 2000
β-Blockers Propranolol, High volumes; detected Calamari et al. 2003
metoprolol in the environment Ternes 1998
Antiepileptics Carbamazepine, High volumes; long-term Andreozzi et al. 2002
phenobarbital prescriptions; persistent
Lipid regulators Statins (e.g., atorvastatin), Long-term prescriptions; Buser et al. 1998
cloﬁbrate  commonly detected Heberer et al. 1997
Antidepressants Fluoxetins, risperidone  Subject of toxicity testing Brooks et al. 2003
Hormone treatments Contraceptive pills, Most extensively studied Arcand-Hoy et al. 1998
17α-ethinyl estradiol, toxicologic properties; Länge et al. 2001
hormone replacement widely detected Purdom et al. 1994
Rodgers-Gray et al. 2000
Antihistamines Loratadine, cetirizine Commonly held 
nonprescription medicine
Abbreviations: NSAIDS, nonsteroidal anti-inﬂammatory drugs; OTC, over-the-counter. also be useful in charting the methods of dis-
posal and the exact volumes concerned. This
project has served as a pilot study, establishing
the need for more specific data, and a more
detailed drug collection study is now under
way to provide accurate information to sup-
plement the proposed model.
The model uses data that describe the per-
centage of the parent compound that passes
through the body unchanged. It is possible that
conjugates could be hydrolyzed back to the
parent compound in the environment. It is
also possible that metabolic products could be
more toxic in the environment than the parent
compound. Where such data are available, they
could be incorporated. They were not, how-
ever, incorporated in the model presented here.
Results
The survey was carried out in southeastern
England during the summer of 2003. The
minimum sample size was exceeded with
392 people interviewed (54.8% female,
45.2% male), closely reﬂecting the actual dis-
tribution in the United Kingdom (51.3%
female, 48.7% male). The subjects were also
spread evenly across age ranges and family
types. Almost everyone (98%) had some type
of pharmaceutical in their house; most
(60.2%) had a mixture of over-the-counter
(OTC) and prescription medicines, whereas
30.7% had only OTC medicines and 9.1%
had only prescription medicines. Responses
indicate that just more than half (52.8%) ﬁn-
ish their medication and hence have none to
dispose of. Around a third (30.7%) keep
them until the expiration date, and 12.2%
dispose of them when the treatment has been
completed. Figure 2 describes the disposal of
unwanted pharmaceuticals. Two-thirds
(63.2%) discard them in household waste,
with the remainder returning them to a phar-
macist (21.8%) or emptying them into the
sink or toilet (11.5%). A small number took
them to municipal waste sites that sometimes
have special waste facilities.
The data can be broken down into the
eight selected pharmaceutical groups to show
how behavior varies with respect to drug type
(Table 4). Nearly 80% of people consume all
of the painkillers that they buy or are pre-
scribed, whereas the figure for antibiotics
(18%) is worryingly low. Household waste
was the most popular disposal method for all
types of drugs. Although the average rate of
sink/toilet disposal for all drug types is 11.5%,
none of the 90 people who had hormone
treatments admitted to flushing them down
the toilet, with the number returning them to
the pharmacy increasing accordingly.
The information on the disposal of two
different types of pharmaceuticals, metoprolol
and ibuprofen, along with figures on the
elimination of the compound in the human
body and WWTW removal efficiencies, was
used to model the relative importance of the
pathways into the environment. Metoprolol
succinate is a β-blocker, mainly used in the
treatment of high blood pressure. It is avail-
able only by prescription in the United
Kingdom. Figure 3 is a mass balance flow
chart showing the fate of 100 units of the par-
ent compound. Only 46.8% of respondents
who had been prescribed β-blockers said that
they finished the prescription. Assuming, as
previously stated, that those people took half
of the medication, then 26.6 units are dis-
posed of and 73.4 units of the active ingredi-
ent are consumed. Because 90% of the
medication taken is modiﬁed by the body, this
leaves 7.3 units of active ingredient that are
introduced to the wastewater system (Huschek
et al. 2004). When combined with the
4.4 units (16.7%) of drugs that are put down
the drain, this results in a total of 11.7 units
entering WWTWs. Here, 83% is removed
(Ternes 1998), leaving 2 units to be dis-
charged into surface water. Of the 26.6 units
that are unused, 4.4 are returned to the phar-
macy whereas 17.7 units, nearly 10 times as
much as is released into the environment from
WWTWs, are put into household waste that
is subsequently taken to a landﬁll. Once there,
some will be removed by biologic and chemi-
cal degradation within the landﬁll, some will
be collected at leachate treatment plants and
subjected to similar processes as in the
WWTWs and then released into surface
water, and some may leach directly into the
surrounding groundwater and possibly rivers.
In the case of metoprolol, household dis-
posal might be a signiﬁcant pathway into the
environment. This is because the drug is not
removed or modified by the body, nor is it
modiﬁed by WWTW processes. The literature
currently reflects a bias toward research of
WWTW treatment rather than landfill
leachate that may not fully address the risks of
pharmaceuticals to the environment. It is also
important to note that the sludge generated
during WWTW treatment may be itself land-
ﬁlled or spread on agricultural land—the risk
of pharmaceuticals is not necessarily removed,
just moved. Millions of tons of sewage sludge
are generated in the European Union every
year. The proportion of the pharmaceutical
load contained within the solid waste products
of WWTWs depends largely on the properties
of the drug, especially the octanol–water coefﬁ-
cient (KOW), which is an indicator of the likeli-
hood that the compound will be partitioned
into the solid phase. Other important inter-
actions are the sorption to organic matter, sur-
face adsorption to mineral constituents, ion
exchange, complex formation with metal ions
such as Ca2+, Mg2+, Fe3+, or Al3+, and hydro-
gen bonding (Diaz-Cruz etal. 2003). Once
these “biosolids” have been spread on agricul-
tural land or landﬁlled, degradation may con-
tinue, but there is also the potential for soil and
groundwater contamination, runoff, and even
adverse effects on plants or animals reared on
the land (Jjemba 2002; Xia etal. 2005).
The same model applied to ibuprofen
(Figure 4) shows that usage is a more promi-
nent pathway than it is for metoprolol.
Results of the survey showed that fewer peo-
ple (20.8%) had any painkillers to dispose of.
Assuming they consumed half of these, only
10.4 units require disposal. Therefore, even
though from the model the rates of elimina-
tion in the body and WWTWs are compara-
ble with those of metoprolol, the ratio of the
active ingredient entering landfill sites com-
pared with that entering surface water from
WWTWs is 5.5:1 for ibuprofen (the ratio for
metoprolol is 8.9:1). This demonstrates that
both human behavior and pharmacologic
properties of the active ingredient are impor-
tant in assessing the signiﬁcance of the differ-
ent pathways into the environment.
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Table 4. Disposal characteristics (%) based on drug type.
When How
Treatment Trash Sink/
Drug Present Empty Expired ﬁnished Other bin toilet Pharmacy Other
Painkiller 94.1 79.2 18.4 2 0.4 69.6 10.9 18.5 1
Antihistamine 45.9 61.4 33 3.7 1.9 75.3 9.1 14.3 1.3
Antibiotic 56.4 17.6 10.5 69.9 2.1 71.4 3.6 14.3 10.7
Antiepileptic 2 66.7 22.2 11.1 0 100 0 0 0
β-Blocker 11.2 46.8 12.8 38.3 2.1 66.7 16.7 16.7 0
Hormone 23.2 68.1 4.3 26.6 1.1 75 0 25 0
Lipid regulator 6.9 41.4 6.9 51.7 0 66.7 0 0 33.3
Antidepressant 9.7 53.7 14.6 29.3 2.4 66.7 0 33.3 0
Other
Pharmacy
Household
waste Sink/toilet
Waste
site
Figure 2. Subjects’ usual disposal methods for
pharmaceuticals. Discussion
Despite advice on pharmaceutical packaging
that recommends the return of unused medi-
cines to pharmacies, or occasionally to flush
them down the toilet, the predominant
method of disposal in the United Kingdom
was found to be via household waste.
Although this result is similar to that found in
the United States by Kuspis and Krenzelok
(1996), the figures for those returning their
unused medication to the pharmacy (21.8%
in the United Kingdom compared with 1.4%
in the United States) and those who disposed
of the medicines down the toilet (11.5% in
the United Kingdom and 35.4% in the
United States) may reflect the disparity
between regulations and advice in the two
regions. The answers given to the survey con-
ducted in the present study suggest that there
may be a signiﬁcant quantity of pharmaceuti-
cals entering the household waste stream in
the United Kingdom. This is of potential con-
cern because medicines deposited in their orig-
inal form in landfill sites bypass the human
body and WWTWs. It is therefore possible
that even though comparatively small quanti-
ties may travel by this pathway, it could have
increased significance because of this avoid-
ance of removal mechanisms. The variation in
these removal rates makes it difﬁcult to gener-
alize the relevance of the different pathways
into the environment for all medicines.
The model described in Figures 3 and 4 is
intended to show that the household disposal
of medicines is worthy of consideration in the
risk assessment and management process. In
its current form, this model is not capable of
predicting the precise amounts of pharmaceu-
ticals entering the environment by each path-
way. However, with the limited information
available, it does show that, under the condi-
tions proposed, the disposal pathway is a
potential cause for concern and should ﬁgure
more prominently in the investigations into
the presence of pharmaceuticals in the aquatic
environment. The model also shows how dif-
ferent drugs will favor different pathways.
More than twice the percentage of people
questioned said they disposed of β-blockers
compared with painkillers. This could be due
to changing prescriptions or the fact that peo-
ple foresee a future use for painkillers. It
could also be related to the patient’s percep-
tion of risk about the relative dangers of the
two types of drugs (Bound et al., in press). 
With other compounds, the dominant
factor could be the metabolism or the stability
within the WWTWs. The model gives ﬁgures
for the proportion of the parent compound
that passes through the body and the
WWTWs unchanged. Some of the other
products of these processes may also have eco-
toxicologic properties. It may be possible to
modify the model where further knowledge
about the pharmaceutical is available. In the
case of metoprolol, Huschek etal. (2004)
found that some of the other metabolic prod-
ucts also showed pharmaceutical activity. If
these are included in the calculation, a total of
34% of the drug was excreted in active forms.
Where this information is known, it could
also be included in the calculation. However,
“active” refers to the pharmacologic properties
that may not necessarily coincide with envi-
ronmental toxicology.
The most straightforward way to eliminate
the risk posed by the disposal pathway would
be to reduce the quantity of drugs being
improperly discarded. One possibility is to
increase the prominence of product labeling
and the provision of stronger advice on how to
dispose of any remaining drugs. The results of
the survey showed that, although half of people
ﬁnished their prescriptions, reasons for disposal
included expiration (30.7%) and completion
of treatment before ﬁnishing the prescription
(12.2%). This is understandable for OTC
medications. However, in the case of prescrip-
tion medication, this indicates that the instruc-
tions that accompany the prescription have not
been adhered to, because completion of the
treatment and the end of the prescription
should coincide if normal practice is followed.
This level of noncompliance (patient not 
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Figure 4. The fate of ibuprofen by units used. 
Total :
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26.6 73.4
Body
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Surface water
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hydrolyzed
83% Removed
Disposal Usage
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17.7
2
Figure 3. The fate of metoprolol by units used. following completely the instructions from
their physician) is similar to estimates else-
where (Donovan and Blake 1992).
Patients may deviate from recommenda-
tions for many reasons: they may be avoiding
unpleasant side effects; they may believe that,
because symptoms have been alleviated, there
is no need to continue medication; or it could
simply be forgetfulness. A possible solution
would be to increase the information given to
patients by doctors and pharmacists about the
need to complete courses of medication and
the importance of safe disposal when medi-
cines remain unused. However, if up to 50%
of patients do not follow advice that could
have important impacts on their own health,
will they be prepared to alter their behavior
based on environmental concerns? A Canadian
survey reported that, although > 50% of peo-
ple said that they read the labels of OTC
medications, only 2% said that they read
product packaging to discover appropriate
disposal methods. However, when directly
prompted about disposal information, 57%
stated that they did (COMPAS Inc. 2002).
These factors would seem to undermine the
efficacy of product labeling as a means of
reducing improper disposal.
Investigations into environmental conta-
mination via landfill leachate (Ahel etal.
1998; Eckel etal. 1993; Holm etal. 1995;
Schwarzbauer etal. 2002; Slack etal. 2005a)
are far less common than similar studies into
pollution from WWTWs. They are also often
concerned with sites that have received large
quantities of pharmaceuticals in bulk as part of
industrial disposal rather than just household
waste. Modern landfill sites are usually
equipped with linings capable of preventing a
high proportion of leachate from escaping into
the surrounding groundwater. Where this is
the case, leachate treatment plants are often
employed to reduce or remove harmful conta-
minants before their release into surface waters.
These facilities are potentially capable of inten-
sive waste management systems partly because
of the low volumes involved compared with
WWTWs or drinking-water plants. Such
processes include ozonation, nanofiltration,
and activated carbon adsorption (Wintgens
etal. 2003; Wu etal. 2004). Advanced facili-
ties such as these are not currently wide-
spread, but they could be introduced to
reduce the release of pharmaceuticals, pesti-
cides, and endocrine disruptors into the
aquatic environment. Older sites and those in
developing countries are unlikely to have
modern membrane liners to prevent leaching,
although some may rely on natural geologic
features to minimize groundwater contamina-
tion. Further studies on the concentrations of
pharmaceutical compounds within landfill
sites and in leachate would be informative,
and if necessary, those sites not equipped with
the necessary treatment facilities could be
upgraded.
Current and proposed risk assessment
guidelines in the European Union (EMEA
2005) and the United States (FDA 1998) do
not consider the disposal pathway when calcu-
lating the predicted environmental concentra-
tions of medicines. Applicants for new licenses
could use studies such as the one presented here
to predict the proportion of medicine that will
be disposed of in general waste using ﬁgures for
local prescription practices and public behavior.
This approach may be considered too time-
consuming when compared, for example, to
earlier “worst-case scenario” approaches
(EMEA 2001) that assume that all of the pre-
scribed drug will end up in the surface water.
But the more recent revisions account for
removal in the body and WWTWs. This opti-
mization of the process means that some com-
pounds that might have been recommended for
assessment under the earlier system will now be
shown to be sufﬁciently safe because a high pro-
portion of the compound is degraded to a less
toxic form. However, if a signiﬁcant proportion
of the drug is not undergoing the transforma-
tion within the patient and WWTWs, there is a
possibility that enough of the active ingredient
would reach the environment to trigger further
investigation. We believe that a complete risk
assessment framework should give some consid-
eration to the disposal pathway. 
Daughton (2003a) advocated the develop-
ment of a database to catalogue the distribution
of prescription and OTC drugs (information
on the latter in particular is difﬁcult to obtain
at the present). Regional variations in the sup-
ply of pharmaceuticals could be coupled with
data on the metabolic breakdown and
WWTW degradation (this could be locally
optimized to include the type of treatment
processes in use in a speciﬁc region, e.g., pri-
mary, secondary, activated sludge) to more
accurately predict the release of a pharmaceuti-
cal in the environment. Furthermore, this
information could be combined with data on
the disposal of unused medicines, as proposed
in this study. Where facilities exist, informa-
tion on returns from pharmacies and hospitals
could also be incorporated to provide a more
effective method for the prediction of environ-
mental concentrations. Knowledge about the
presence of drugs in household waste could
benefit the management of risks to the
environment. Minimizing the disposal path-
way could be more effective and less costly
than extensive WWTW modifications or
other remediation steps.
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